Halozyme Therapeutics is in an unusual spot three days after its 23% earnings pop — the stock has stalled at $102.62 while shorts, far from covering, have barely moved.
Short interest is marginally lower than it was pre-earnings, but the scale of the retreat is telling. SI has edged down just 1.7% on the week to 11.98% of the free float — essentially unchanged from the 12.3% reading that preceded the blowout Q2 print. Shorts caught off-side on August 6 have not rushed for the exit. The lending market explains why: availability runs at 198%, meaning there are roughly two shares available to borrow for every one currently lent out, and cost to borrow remains negligible at 0.57%. The borrow market is as relaxed as it has been all month — no friction, no urgency. What's changed since the pre-earnings note is the direction of availability: it has tightened from the 262% seen a fortnight ago, and is now approaching the tightest level of the past year. That compression is worth watching — it reflects growing demand for borrows even as shorts hold their ground.
Options are not flashing alarm. The put/call ratio sits at 0.42, virtually in line with its 20-day average of 0.41, and the z-score of 0.40 suggests nothing exceptional in either direction. For comparison, the 52-week high on the PCR was 0.63 — the current reading is well below that. Options traders who might have hedged into earnings have not rebuilt meaningful downside protection since the move. The picture across lending and options, taken together, points to a market that has absorbed the earnings shock without repositioning dramatically in either direction.
The Street, however, has repositioned. Analysts moved sharply after the print. Leerink Partners upgraded to Outperform and lifted its target from $83 to $110. TD Cowen raised from $96 to $105. HC Wainwright moved from $95 to $115. Wells Fargo kept its Equal-Weight but raised from $75 to $95 — a meaningful concession from the skeptical camp. The consensus sits at a clean buy, with the highest-rated analyst recommendation score in its factor peer group at the 98th percentile. Forward EPS estimates rank in the 92nd percentile for year-on-year growth. The bear case centres on long-term royalty sustainability — management has previously trimmed its royalty guidance, and newer partner therapies like RYBREVANT SC bear more of the growth burden going forward. The bull case is royalty compounding: the ENHANZE platform has a long runway of partnerships and Halozyme collects without the clinical risk.
Valuation has re-rated. The P/E has moved from roughly 8.4× a month ago to 10.6× today — a meaningful expansion in thirty days for a stock that was already pricing in growth. Price-to-book has similarly climbed, up more than 2 full turns over the same window. At 10.6× earnings and 9.7× cash flow, HALO is no longer cheap on the numbers — but the forward growth score makes the case that the multiple is not yet stretched by biotech standards.
Peer performance this week adds context without contradicting the HALO story. VRTX gained 10.6% and NTRA rose 13.6% — suggesting broad biotech momentum helped carry HALO's post-earnings consolidation, while EXEL fell 8.3%, a reminder that not all biotech names are moving in the same direction. The next earnings event is flagged for November 3 — until then, the question is whether shorts gradually reduce a still-elevated 12% float position as the stock re-rates, or whether continued availability compression finally begins to bite.
See the live data behind this article on ORTEX.
Open HALO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
